Compugen expands to California to develop mAb drug candidates

Monday, April 2, 2012 03:31 PM

Compugen Inc., a Canadian therapeutic product discovery company, has established new operations in South San Francisco, Calif., for the development of oncology and immunology monoclonal antibody (mAb) drug candidates against Compugen-discovered targets.

The expansion follows the Compugen’s December 2011 announcement of its intention to significantly broaden and accelerate its mAb activities. At that time, and in partial support of its mAb operations expansion, the company also announced an $8 million research funding agreement signed with Baize Investments, an Israeli private corporation that invests in innovative medical technologies.

Compugen Inc. hopes to translate the growing portfolio of novel mAb targets being discovered and validated by the parent company (Compugen Ltd. based Israel) into promising mAb drug candidates for licensing and partnering. The new operations will be lead by Mary Haak-Frendscho, Ph.D., as executive chairperson and John J. Hunter, Ph.D., as vice president of antibody R&D and site head.

The new operations will be located in recently secured purpose-built facilities with relevant laboratory equipment. By locating its mAb operation in the birthplace of biotech, Compugen Inc. hopes to gain access to some of the best biologics talent in the industry and supportive infrastructure. Furthermore, with its new capabilities, the company anticipates it will significantly increase the number of mAb product candidates developed against novel Compugen-discovered targets by performing key activities more effectively and efficiently in-house compared with solely using third parties as previously intended.

Dr. Anat Cohen-Dayag, president and CEO of Compugen Ltd., said, "We are at a pivotal moment where Compugen's unique monoclonal antibody targets discovery platform is delivering high quality, novel mAb targets that enable the development of new drug candidates to address unmet medical needs. We enthusiastically look forward to leveraging the commercial potential of these pioneering and industry leading predictive discovery capabilities by licensing out — at significantly greater values — the differentiated mAb product candidates against these novel targets, rather than the targets.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs